ReviewMolecular neurobiology2025
Melatonin Supplementation in Alzheimer's disease: The Potential Role in Neurogenesis.
Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Status of research on the application of melatonin in insomnia based on bibliometric visualization analysis and development trends.Frontiers in psychiatry · 2025Pooled it
- From General-Purpose to Disease-Specific Features: Aligning LLM Embeddings on a Disease-Specific Biomedical Knowledge Graph for Drug Repurposing.bioRxiv : the preprint server for biology · 2026Article
- Perspectives on Alzheimer's Disease Treatment Based on Counteracting Oxidative Stress.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melatonin supplementation shows potential therapeutic effects in Alzheimer's disease (AD) by targeting impaired neurogenesis. Neurogenesis, the formation of new neurons after development, involves proliferation, migration, differentiation, and survival of neurons. Impaired neurogenesis is associated with AD, specifically in the subventricular zone (SVZ) and subgranular zone (SGZ), leading to hippocampal degeneration and memory impairment. Melatonin positively effects AD by regulating amyloid beta (Aβ)-induced neuroinflammation, reducing tau hyperphosphorylation, and enhancing adult neurogenesis through various signaling pathways. In addition, it has anti-apoptotic, antioxidative, and anti-inflammatory properties, suggesting its potential as a treatment option for AD progression. Furthermore, melatonin and sleep are closely linked, and an increase in sleep duration positively affects Aβ deposition. This review aims to examine the impact of AD pathologies on neurogenesis and explore the mechanisms by which melatonin may alleviate these pathologies, potentially promoting neurogenesis.
Indexed as
Identifiers
40439856What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.